SCHEMBL15540769

SCHEMBL15540769

Cc1nc2ccc(O)cc2n1C(C)c1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
DCTPP1 Q9H773 1/20 0.46
BRD4 O60885 3/20 0.41
LMNA P02545 2/20 0.41
KDM4E B2RXH2 1/20 0.41
CASP1 P29466 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TP53 P04637 1/20 0.41
PIK3CD O00329 2/20 0.40
PIK3CA P42336 2/20 0.40
MTOR P42345 2/20 0.40
TSHR P16473 1/20 0.40
HDAC1 Q13547 2/20 0.39
HDAC8 Q9BY41 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39
TYR P14679 1/20 0.39
APAF1 O14727 1/20 0.38
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15553037 0.74 MEN1 (0.44) MEN1KMT2ADCTPP1BRD4TP53
SCHEMBL12789515 0.72 HSD17B10 (0.47) MEN1KMT2ALMNAKDM4EHSD17B10
SCHEMBL19023308 0.70 KDM4E (0.55) MEN1KMT2ALMNAKDM4EHDAC1
SCHEMBL6170399 0.69 HSD17B10 (0.48) LMNAKDM4EHSD17B10
SCHEMBL9538253 0.69 LMNA (0.56) MEN1KMT2ALMNAKDM4ENPSR1
SCHEMBL16756327 0.68 TP53 (0.46) MEN1KMT2ABRD4LMNAKDM4E
SCHEMBL14247296 0.68 MEN1 (0.45) MEN1KMT2ADCTPP1BRD4LMNA
SCHEMBL14247421 0.68 MEN1 (0.45) MEN1KMT2ADCTPP1BRD4LMNA
SCHEMBL19836554 0.67 CSNK1E (0.43) BRD4LMNAHSD17B10TSHR
SCHEMBL23042575 0.66 MEN1 (0.40) MEN1KMT2ALMNAKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2858983-B1 TNF-ALPHA MODULATING BENZIMIDAZOLES UCB BIOPHARMA SPRL (BE) 2018-04-18 EP disclosed
US-9550737-B2 TNF -α modulating benzimidazoles UCB BIOPHARMA SPRL (BE) 2017-01-24 US disclosed
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles UCB BIOPHARMA SPRL (BE) 2015-06-04 US disclosed
EP-2858983-A1 TNF -ALPHA MODULATING BENZIMIDAZOLES UCB Biopharma SPRL (BE) 2015-04-15 EP disclosed
WO-2013186229-A1 TNF -ALPHA MODULATING BENZIMIDAZOLES UCB PHARMA S.A. (BE) 2013-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles TNF, TNFRSF1A, NFKBIA MEN1 3836/4885KMT2A 3732/4885DCTPP1 2186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.